Cochlear Ltd (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Ltd (ASX: COH)
Latest News
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
7 ASX 200 directors sell huge chunks of company shares
Healthcare Shares
Why is the Cochlear share price in the red today?
Share Market News
5 things to watch on the ASX 200 on Tuesday
Dividend Investing
9 ASX 200 shares with ex-dividend dates next week
Share Fallers
Why Cochlear, Nufarm, Origin Energy, and Pilbara Minerals shares are crashing today
Earnings Results
Cochlear shares sink 8% on FY24 earnings miss
Earnings Results
Cochlear share price on watch after reporting strong FY24 profit and dividend growth
Blue Chip Shares
5 top ASX 200 shares with 'no credible competition'
How to invest
Shares vs. property: Why it pays to be patient
How to invest
These ASX 200 stocks turned $20,000 into $100,000+ in 10 years
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
17 Sep 2024 | $2.1000 | 80.00% | Final | 10 Oct 2024 |
21 Mar 2024 | $2.0000 | 70.00% | Interim | 15 Apr 2024 |
18 Sep 2023 | $1.7500 | 70.00% | Final | 11 Oct 2023 |
21 Mar 2023 | $1.5500 | 35.00% | Interim | 14 Apr 2023 |
21 Sep 2022 | $1.4500 | 40.00% | Final | 17 Oct 2022 |
28 Mar 2022 | $1.5500 | 0.00% | Interim | 21 Apr 2022 |
23 Sep 2021 | $1.4000 | 0.00% | Final | 18 Oct 2021 |
25 Mar 2021 | $1.1500 | 0.00% | Interim | 20 Apr 2021 |
19 Sep 2019 | $1.7500 | 100.00% | Final | 14 Oct 2019 |
25 Mar 2019 | $1.5500 | 100.00% | Interim | 16 Apr 2019 |
17 Sep 2018 | $1.6000 | 100.00% | Final | 10 Oct 2018 |
19 Mar 2018 | $1.4000 | 100.00% | Interim | 12 Apr 2018 |
19 Sep 2017 | $1.0000 | 100.00% | Final | 11 Oct 2017 |
15 Mar 2017 | $1.3000 | 100.00% | Interim | 06 Apr 2017 |
07 Sep 2016 | $1.2000 | 100.00% | Final | 29 Sep 2016 |
10 Mar 2016 | $1.1000 | 100.00% | Interim | 01 Apr 2016 |
02 Sep 2014 | $1.2700 | 20.00% | Final | 25 Sep 2014 |
20 Feb 2006 | $0.4500 | 100.00% | Interim | 14 Mar 2006 |
26 Aug 2005 | $0.4500 | 100.00% | Final | 22 Sep 2005 |
19 Feb 2004 | $0.3500 | 100.00% | Interim | 17 Mar 2004 |
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Cochlear Ltd
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
COH Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
23 Dec 2024 | $292.27 | $3.19 | 1.10% | 60,931 | $289.14 | $293.00 | $288.83 |
20 Dec 2024 | $289.08 | $-2.03 | -0.70% | 209,828 | $291.12 | $292.75 | $289.00 |
19 Dec 2024 | $291.11 | $-3.32 | -1.13% | 173,595 | $292.00 | $292.75 | $287.67 |
18 Dec 2024 | $294.43 | $-3.86 | -1.29% | 169,488 | $297.60 | $298.67 | $294.43 |
17 Dec 2024 | $298.29 | $5.21 | 1.78% | 107,844 | $293.64 | $299.24 | $293.01 |
16 Dec 2024 | $293.08 | $1.70 | 0.58% | 188,751 | $291.24 | $296.31 | $289.90 |
13 Dec 2024 | $291.38 | $0.87 | 0.30% | 124,361 | $288.74 | $292.51 | $287.34 |
12 Dec 2024 | $290.51 | $-2.93 | -1.00% | 129,951 | $292.83 | $294.78 | $288.65 |
11 Dec 2024 | $293.44 | $-2.18 | -0.74% | 116,176 | $295.89 | $297.21 | $291.58 |
10 Dec 2024 | $295.62 | $-5.95 | -1.97% | 125,392 | $300.00 | $300.80 | $292.00 |
09 Dec 2024 | $301.57 | $0.12 | 0.04% | 86,941 | $302.56 | $307.16 | $300.51 |
06 Dec 2024 | $301.45 | $-3.35 | -1.10% | 97,085 | $300.81 | $302.52 | $298.22 |
05 Dec 2024 | $304.80 | $1.64 | 0.54% | 103,719 | $303.46 | $305.66 | $303.46 |
04 Dec 2024 | $303.16 | $-1.70 | -0.56% | 82,020 | $304.00 | $306.59 | $300.38 |
03 Dec 2024 | $304.86 | $2.44 | 0.81% | 114,230 | $303.18 | $306.98 | $302.57 |
02 Dec 2024 | $302.42 | $-1.82 | -0.60% | 116,441 | $304.94 | $305.60 | $299.48 |
29 Nov 2024 | $304.24 | $-3.43 | -1.11% | 75,203 | $308.58 | $308.58 | $304.02 |
28 Nov 2024 | $307.67 | $1.81 | 0.59% | 102,755 | $308.70 | $309.63 | $306.85 |
27 Nov 2024 | $305.86 | $-0.42 | -0.14% | 122,639 | $309.20 | $309.20 | $304.59 |
26 Nov 2024 | $306.28 | $4.72 | 1.57% | 117,482 | $306.43 | $307.00 | $303.01 |
25 Nov 2024 | $301.56 | $3.33 | 1.12% | 231,307 | $300.00 | $301.60 | $298.01 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
13 Nov 2024 | Dig Howitt | Issued | 4,309 | $1,279,471 |
Issue of securities. 27,333 rights
|
13 Nov 2024 | Dig Howitt | Issued | 13,445 | $3,992,223 |
Issue of options.
|
30 Oct 2024 | Dig Howitt | Sell | 10,982 | $3,132,072 |
On-market trade.
|
29 Oct 2024 | Dig Howitt | Exercise | 11,000 | $2,266,660 |
Exercise of options.
|
29 Oct 2024 | Dig Howitt | Buy | 11,000 | $2,266,660 |
Exercise of options.
|
23 Sep 2024 | Dig Howitt | Issued | 3,082 | $862,620 |
Issue of securities. 23,024 Rights
|
13 Sep 2024 | Dig Howitt | Sell | 2,314 | $668,560 |
On-market trade.
|
13 Sep 2024 | Dig Howitt | Buy | 2,314 | $476,822 |
Exercise of options.
|
13 Sep 2024 | Dig Howitt | Exercise | 2,314 | $476,822 |
Exercise of options.
|
12 Sep 2024 | Dig Howitt | Exercise | 5,000 | $1,030,300 |
Exercise of options.
|
12 Sep 2024 | Dig Howitt | Sell | 5,000 | $1,452,900 |
On-market trade.
|
12 Sep 2024 | Dig Howitt | Buy | 5,000 | $1,030,300 |
Exercise of options.
|
29 Aug 2024 | Karen Penrose | Buy | 100 | $29,834 |
On-market trade.
|
26 Aug 2024 | Michael del Prado | Buy | 95 | $19,855 |
On-market trade. US $
|
22 Aug 2024 | Christine McLoughlin | Buy | 250 | $76,392 |
On-market trade.
|
21 Aug 2024 | Karen Penrose | Buy | 49 | $14,894 |
On-market trade.
|
20 Aug 2024 | Karen Penrose | Buy | 48 | $14,978 |
On-market trade.
|
16 Aug 2024 | Dig Howitt | Exercise | 18,314 | $5,596,025 |
Exercise of options.
|
16 Aug 2024 | Dig Howitt | Issued | 7,384 | $2,256,255 |
Conversion of securities.
|
16 Aug 2024 | Dig Howitt | Expiry | 2,903 | $887,040 |
Options expired.
|
16 Aug 2024 | Dig Howitt | Issued | 18,314 | $5,596,025 |
Issue of options.
|
16 Aug 2024 | Dig Howitt | Expiry | 655 | $200,141 |
As advised by the company. 27,326 Rights, lapsed
|
16 Aug 2024 | Dig Howitt | Exercise | 7,384 | $2,256,255 |
Conversion of securities. 19,942 Rights
|
12 Mar 2024 | Dig Howitt | Buy | 279 | $60,621 |
Exercise of options.
|
12 Mar 2024 | Dig Howitt | Exercise | 279 | $60,621 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Ms Christine Frances McLoughlin | Non-Executive Director | Nov 2020 |
Ms McLoughlin has experience as a director on the boards of ASX Top 50 Companies in financial services (including banking, life insurance, superannuation, asset management and general insurance), resources, health insurance and infrastructure sectors over the past 14 years. Other boards are Chairman of the Suncorp Group Limited. Co-founder and Chairman of the Minerva Network. Former directorships include Chairman and Director of Venues NSW and Chairman of Destination NSW. Director, nib Holding Limited, Whitehaven Coal Limited, Spark Infrastructure, the McGrath Foundation and more recently the Chancellor of the University of Wollongong. She is Chair of the People and Culture Committee and member of the Risk and Product and Services Innovation Committee.
|
Mr Michael Grenfell Daniell | Non-Executive Director | Jan 2020 |
Mr Daniell has over 40 years of experience in the medical device industry with executive leadership experience. He is Former Managing Director and CEO of Fisher & Paykel Healthcare Corporation Limited responsible for the global business and operations including the design, manufacture and marketing of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. Other directorships are Director of Fisher & Paykel Healthcare Corporation Ltd; Director, Tait International Limited; Director, Medical Research Commercialisation Fund. Former directorships include Advisory Board Chair, Te Titoki Mataora (NZ). He is Chair of the Product and Services Innovation Committee and member of the Risk and Medical Science Committee.
|
Ms Catriona Alison Deans | Non-Executive DirectorNon-Executive Chairman | Jan 2015 |
Ms Deans has experience leading technology enabled businesses across e-commerce, media and financial services. Deans was former Chief Executive Officer of netus, Hoyts Cinemas, ecorp and eBay Australia and New Zealand. Other directorships include Director of Ramsay Health Care Limited, Calix Limited, Deputy Group Pty Ltd and Fitness Passport Pty Ltd. Director of The Observership Program. Former directorships include SCEGGS Darlinghurst Limited, Westpac Banking Corporation, Insurance Australia Group Limited and Social Ventures Australia. She was former Member of AICD Corporate Governance Committee.
|
Ms Karen Lee Collett Penrose | Non-Executive Director | Jul 2022 |
Ms Penrose has executive career in senior leadership and Chief Financial Officer roles in financial services. She is a company director, having served on the boards of a number of ASX100 companies and experienced across health care, financial services, property and infrastructure industries. Other boards include Director, Ramsay Health Care Limited, Bank of Queensland Limited and Reece Limited. Director, Ramsay General De Sante (associated with Karen's directorship of Ramsay Health Care Limited), Marshall Investments Pty Limited, NSW Waratahs Ltd and Waratahs Rugby Pty Ltd. Former directorships are Vicinity Centres, Estia Health Ltd, Rugby Australia Limited. She is Chair of the Risk Committee and member of the People and Culture and Product and Services Innovation Committee.
|
Mr Glen Francis Boreham | Non-Executive Director | Jan 2015 |
Mr Boreham Led organisations in information technology, new media and the creative industries through periods of rapid change and innovation. He is Former Managing Director of IBM Australia and New Zealand. Other boards include Strategic Advisor, IXUP. Former directorships were held with Southern Cross Media Group, Data#3 and Link Group. Chairman of Screen Australia, Advance (Global Australian Network), Business School and Industry Advisory Board for the University of Technology, Sydney and Advisory Board IXUP. he is member of the Risk Committee, People and Culture and Product and Services Innovation Committees.
|
Professor Bruce Gregory Robinson | Non-Executive Director | Dec 2016 |
Mr Robinson has over 20 years of leadership experience as an academic physician/scientist across research, healthcare and medicine, and tertiary education. He is Co-Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research and Chair of Research, North Sydney Local Health District. He is Former Dean of The University of Sydney's Sydney Medical School and Head of Medicine at Sydney's Royal North Shore Hospital. Other boards are Director, MaynePharma, QBiotics, Ecofibre and EOF BIO LLC (associated with the Ecofibre directorship). Deputy Chairman (former Chairman), Hoc Mai Foundation. Senior Advisor to McKinsey & Company and Advisor to MinterEllison. Former directorships include Chairman of National Health and Medical Research Council; chairman of Medical Benefits Schedule Review Taskforce; Director, Lorica Health Pty Limited, Firefly and Digital Health Agency CRC and Woolcock Institute of Medical Research. He is Chair of Medical Science Committee and member of the Product and Services Innovation Committees.
|
Mr Dig Howitt | PresidentChief Executive OfficerManaging Director | Jul 2017 |
Mr Howitt has experience across the Company in roles including Chief Operating Officer, President, Asia Pacific and SVP, Manufacturing and Logistics. Prior to joining Cochlear he worked for Boston Consulting Group and held a General Management role at Boral. Dig is a member of the Champions of Change Coalition, STEM group. He is member of the Medical Science and Product and Services Innovation Committees.
|
Mr Michael del Prado | Non-Executive Director | Jan 2022 |
Mr Prado has over 34 years of global experience in the medical device and pharmaceutical industries with senior executive leadership roles in Johnson & Johnson medical device businesses in the US, Asia-Pac and EMEA. He is Former Company Group Chairman of Ethicon, a surgical company. Other boards are Ambu A/S. Former directorships include Co-lead Director of Verb Surgical. Advisory Board, Singapore Management University Lee Kong Chian School of Business. He is member of the Medical Science, People and Culture and Product and Services Innovation Committee.
|
Ms Caroline Louise Clarke | Non-Executive Director | Sep 2024 |
Ms Clarke has more than 30 years of commercial experience, including 20 years of executive roles at medical devices, medical equipment and healthcare services businesses in large global companies. Ms Clarke was most recently CEO and Executive Vice President ASEAN Pacific for Philips . Ms Clarke will become a member of the People and Culture Committee, the Product & Services Innovation Committee .
|
Ms Kristy Jo | Company Secretary | Apr 2024 |
-
|
Mr Rob McGrory | Company Secretary | Apr 2024 |
-
|
Stu Sayers | Chief Financial Officer |
-
|
|
Jan Janssen | Chief Technology Officer |
-
|
|
Kristy Jo | Company Secretary |
-
|
|
Rob McGrory | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited i | 28,724,005 | 43.86% |
J P Morgan Nominees Australia Pty Limited | 10,419,733 | 15.91% |
Citicorp Nominees Pty Limited | 7,185,958 | 10.97% |
National Nominees Limited | 1,260,072 | 1.92% |
BNP Paribas Noms Pty Ltd | 1,248,618 | 1.91% |
BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 1,234,623 | 1.89% |
HSBC Custody Nominees (Australia) Limited <Ntcomnwlth Super Corp A/C> | 473,902 | 0.72% |
Australian Foundation Investment Company Limited | 324,174 | 0.49% |
Netwealth Investments Limited <Wrap Services A/C> | 322,512 | 0.49% |
BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 311,198 | 0.48% |
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 257,130 | 0.39% |
HSBC Custody Nominees (Australia) Limited Gsco Eca | 250,716 | 0.38% |
Mr Christopher Graham Roberts | 172,387 | 0.26% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 166,930 | 0.25% |
Custodial Services Limited <Beneficiaries Holding A/C> | 148,099 | 0.23% |
HSBC Custody Nominees (Australia) Limited ii | 146,653 | 0.22% |
BNP Paribas Nominees Pty Ltd <Clearstream> | 131,365 | 0.20% |
HSBC Custody Nominees (Australia) Limited <Euroclear Bank Sa Nv A/C> | 125,730 | 0.19% |
Ubs Nominees Pty Ltd | 95,069 | 0.15% |
Ioof Investment Services Limited <Ips Superfund A/C> | 72,784 | 0.11% |